Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release…
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules
- Published
- 9 Apr 2025
- Units affected
- 14,863 bottles
- Agency
- FDA
- Country
- United States
The hazard
CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10.
- Brand / company
- Breckenridge Pharmaceutical, Inc.
- Codes / lots
- Lot 240909C, Exp Date 03/31/2027
- Distribution
- Nationwide in the US
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 9 Apr 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.